Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

NIAID reports phase IIb results on VRC-01 for HIV prevention

Jan. 27, 2021

FDA approves Cabenuva long-acting regimen for HIV-1 infection in adults

Jan. 22, 2021

A humanized mouse HIV latency model to test HIV cure strategies

Jan. 12, 2021

ViiV Healthcare discovers compounds for HIV infection

Jan. 8, 2021

Vir initiates phase I trial of HIV T-cell vaccine VIR-1111

Jan. 8, 2021

European Commission approves cabotegravir and rilpivirine long-acting injectable for HIV

Dec. 22, 2020

Merck & Co. discovers new compounds for HIV infection

Dec. 16, 2020

ViiV Healthcare divulges new HIV1 inhibitors

Nov. 24, 2020

Phase II/III CAPELLA study of lenacapavir meets primary endpoint

Nov. 19, 2020

Gilead Sciences patents HIV protease inhibitors

Nov. 10, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.